# SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases

Source: https://onco.cc/trials/nct06794086/  
OnCo record `nct06794086` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in colorectal cancer, run by Jun Huang, now recruiting.

## Summary

SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases is a phase 3, interventional study registered as NCT06794086 by Jun Huang, with a registry enrolment figure of 24 participants, started 2025-04-10 and due to reach its primary completion in 2026-06-20. Interventions recorded: Stereotactic body radiation therapy; PD-1 Monoclonal Antibody; Chemotherapy. Conditions listed: Colorectal Cancer; Liver Metastases. Primary outcome: ORR. Colorectal eligibility wording from the registry: "Patients with pMMR/MSS colorectal adenocarcinoma;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: SPARKLE-L
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06794086
- Phase: 3
- Setting: SBRT Combined With PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases: A Prospective, Multicenter, Single-arm, Phase II Clinical Study (SPARKLE-L)
- Sponsor: Jun Huang
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT06794086: https://clinicaltrials.gov/study/NCT06794086

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06794086.json